Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K
Jpn J Surg. 1981;11(4):291-6. doi: 10.1007/BF02468770.
Postoperative long term cancer chemotherapy (PLCC) with the combination of Mitomycin-C, FT-207, a furanyl analog of 5-fluorouracil, and PSK, an immunopotentiator, was prescribed for patients with advanced gastric cancer. Five year survival rates for all stage III and stage IV patients were 52.8 and 19.3 per cent in the PLCC group. The rates were 26.7 and 2.2 per cent in the control groups (p less than 0.05). In curative cases of stage IV, the 5-year survival rate was 50.0% in the PLCC group while the rate was 11.1% in the controls. Mean survival time of patients with peritoneal dissemination or hepatic metastases was 12.8 and 10.9 months, respectively, for the PLCC group, in contrast to the lower 6.4 and 4.3 months for the controls. Thus, the 5-year survival rate of advanced gastric cancer patients in stage III and stage IV was markedly improved when these patients were treated with the protocol. Our findings clearly show that adjuvant chemotherapy should be administered for a long period postoperatively in order to achieve a significant improvement in patients with gastric cancer.
对于晚期胃癌患者，采用丝裂霉素 - C、FT - 207（5 - 氟尿嘧啶的呋喃类似物）和免疫增强剂PSK联合进行术后长期癌症化疗（PLCC）。PLCC组中所有III期和IV期患者的五年生存率分别为52.8%和19.3%。对照组的这一比率分别为26.7%和2.2%（p小于0.05）。在IV期治愈病例中，PLCC组的5年生存率为50.0%，而对照组为11.1%。PLCC组中腹膜播散或肝转移患者的平均生存时间分别为12.8个月和10.9个月，相比之下，对照组较低，分别为6.4个月和4.3个月。因此，当采用该方案治疗时，III期和IV期晚期胃癌患者的5年生存率显著提高。我们的研究结果清楚地表明，为了使胃癌患者有显著改善，术后应长期进行辅助化疗。
